ClinicalTrials.gg
RecruitingNCT07586904Updated May 14, 2026

Efficacy and Safety of Neoadjuvant Cadonilimab Plus High-Dose Recombinant Human Interferon α1b in Stage III/IV Melanoma.

An Early Phase 1 interventional study of Cadonilimab and Recombinant Human Interferon α1b Combination Therapy in Melanoma (Skin Cancer), sponsored by Xijing Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-05-14.

Sponsored by Xijing Hospital · Early Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 6 months after the study started (first participant enrolled May 2025, registered Nov 2025).
  • Started May 2025; still recruiting 1 year 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Early Phase 1
Study type
Interventional
Enrollment
10
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 203 studies in Melanoma with a site in China — 83 open to participants now, 95 under way, 5 of them phase 3. Melanoma · China.

Planned enrollment
175th of 189
10 · median 50
Started
2025
with 22 others
Phase 1
57 of 203
19 open now
Primary completion
2026-12
later than 38 of 94 live
Registered
173rd of 203
by date
Lead sponsor
5 of 203
Xijing Hospital

Among the 203 studies in Melanoma with a site in China, this one is the 175th largest by planned enrollment of the 189 interventional ones that give a count, is one of 23 that started in 2025, is one of 57 in phase 1, reaches primary completion later than 38 of the 94 other live ones, and was the 173rd registered.

Melanoma

3,374 studies on the registry are indexed under Melanoma; 579 are open to participants now.

Browse Melanoma studies →

Open to participants now

83 of the 203 studies in Melanoma with a site in China are open now. Recruiting first, the newest first:

78 more — sign in →

All 83 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 467 Melanoma studies recruiting now, 379 (81%) set no upper age limit and 49 (10%) stop at 75 or younger; 47 take children under 18; 29 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 203 studies in Melanoma with a site in China, or all of them as a file.
02

Study summary

  1. Primary Objective

    To evaluate the efficacy and safety of cadonilimab in combination with high-dose recombinant human interferon α1b injection as neoadjuvant therapy in patients with stage III/IV melanoma. Assessments include:

    Target lesion response (complete response [CR], partial response [PR], stable disease [SD], progressive disease [PD]) Objective response rate (ORR) Pathological response rate (pathological complete response [pCR], near pCR, pathological partial response [pPR], pathological non-response [pNR]) Incidence of all adverse events (AEs) and serious adverse events (SAEs) Changes from baseline in physical examinations, vital signs, and laboratory test results.

  2. Exploratory Objectives To investigate the correlation between treatment efficacy/patient outcomes and:PD-L1 expression in tumor tissue CD8+ T-cell infiltration Tumor mutational burden (TMB).
  3. Study Significance To conduct a preliminary exploration in support of future multicenter clinical studies.
03

Conditions studied

  • Melanoma (Skin Cancer)

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Voluntarily participate in this trial, sign the form, and be between 18 and 75 years of age, regardless of gender.
  • Patients with histopathologically or confirmed stage III or resectable stage IV malignant melanoma.

    • Stage III is defined as the presence of at least one clinically accessible lymph node or in-transit metastasis.
    • Resectable stage IV is defined as a single distant metastasis, excluding or any other metastases that cannot be completely surgically resected.
    • Mucosal or ocular melanomas are excluded.
    • Melanomas of unknown primary origin are excluded.
  • Have not received treatment with , PD-L1, or PD-L2 antibodies, anti-CTLA4 antibodies, interferon (IFN), targeted therapy, radiotherapy, or systemic chemotherapy within the past month.
  • Have an expected survival period of ≥ 6 months.
  • Have at least one according to version 1.1.
  • Have an performance status score of 0 or 1.
  • Have adequate organ function, as indicated by the following laboratory values (within 4 weeks prior to the start of study treatment):

    1. (ANC) ≥ 1.5 × 10⁹/L
    2. ≥ 100 × 10⁹/L
    3. ≥ 90 g/L (no blood transfusion within 14 days prior to enrollment)
    4. Serum creatinine ≤ 1.5 × (ULN)
    5. Serum total ≤ 1.5 × ULN
    6. (SGOT) and ALT (SGPT) ≤ 2.5 × ULN or ≤ 5 × ULN (for patients with liver metastases)
    7. (PT)/International Normalized Ratio (INR) and activated partial thromboplastin time (aPTT) ≤ 1.5 × ULN (unless the subject is receiving anticoagulant therapy, in which case PT or aPTT must be within the therapeutic range intended for the anticoagulant used).

      8.Female patients of must have a negative urine or serum pregnancy test within 7 days prior to receiving the first dose of the study drug.

      9.Female patients enrolled in the study must be willing to use appropriate methods until 12 months after the last dose of the study drug.

Exclusion criteria

Exclusion Criteria:

  • The patient is currently participating, or has participated within 4 weeks prior to the first dose of the study drug, in another interventional clinical trial of drugs or medical devices.
  • The patient has received any anti-tumor therapy within the past month, including but not limited to chemotherapy, radiotherapy, immunotherapy (e.g., , anti-PD-L1, or anti-CTLA-4 antibodies, or any other antibody targeting T-cell co-regulatory pathways), etc.
  • The patient has received systemic therapy (>10 mg/kg prednisone or equivalent) within two weeks prior to the first dose, or any other form of medication.
  • The patient has a known history of hematologic , primary brain tumor, sarcoma, or another primary solid tumor, unless the patient has been cured and has had no evidence of recurrence for 5 years. Exceptions include cured basal cell carcinoma of the skin and carcinoma in situ of the cervix.
  • The patient has known central nervous system and/or carcinomatous meningitis.
  • The patient has a history of severe to another monoclonal antibody (mAb) therapy.
  • The patient has had an active disease requiring systemic treatment (e.g., with corticosteroids or immunosuppressive drugs) within the past 2 years, and related replacement therapies (e.g., thyroxine, insulin, or physiologic corticosteroid replacement for renal or pituitary insufficiency). Exceptions include patients with vitiligo, type I diabetes, childhood asthma/atopy.
  • Other severe, uncontrolled concomitant diseases that may affect protocol compliance or interpretation of results, including active opportunistic or advanced (severe) infections; uncontrolled diabetes; cardiovascular disease (e.g., Class III or IV heart failure as defined by the classification, second-degree or greater heart block, myocardial infarction within the past 6 months, unstable arrhythmias or unstable angina, cerebral infarction within 3 months); pulmonary disease (interstitial lung disease, obstructive pulmonary disease, history of symptomatic bronchospasm); positivity; positivity; or HBcAb positivity with detectable HBV DNA (quantitative limit ≥500 IU/mL); or a documented history of tuberculosis.
  • The patient has received a within 4 weeks prior to the first dose; hematopoietic growth factors (e.g., colony-stimulating factors, erythropoietin) within 2 weeks prior to treatment initiation; or major surgical procedures (excluding diagnostic surgery) within 2 weeks prior to treatment initiation.
  • The patient has a known psychiatric or substance use disorder that would interfere with cooperation with trial requirements.
  • The patient is pregnant or breastfeeding, or plans to become pregnant or father a child during the study period.
  • Any other severe, acute, or chronic medical or laboratory abnormality that, in the investigator's judgment, could increase the risk associated with study participation or could interfere with the interpretation of study results.
Terms in these criteria, in plain language(27)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Early Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
10 participants (estimated)

Study arms

  • Experimental
    Cadonilimab and Recombinant Human Interferon α1b Combination Therapy Arm

    Drug: Cadonilimab and Recombinant Human Interferon α1b Combination Therapy

Interventions

  • DrugCadonilimab and Recombinant Human Interferon α1b Combination Therapy

    Cadonilimab: 10 mg/kg administered via intravenous infusion every 3 weeks. The neoadjuvant treatment course consists of 4 cycles, totaling 3 months. Recombinant Human Interferon α1b Injection: 600 μg administered subcutaneously every other day. The neoadjuvant treatment course is 3 months. If intolerable (e.g., occurrence of Grade 3 or 4 adverse reactions or other qualifying events), the dose should be reduced to 300 μg subcutaneously every other day.

06

What researchers measure

Primary outcomes

  1. Systolic blood pressure

    Systolic blood pressure

    Time frame: through study completion, an average of 3 months

  2. respiratory rate

    respiratory rate

    Time frame: through study completion, an average of 3 months

  3. body temperature

    body temperature

    Time frame: through study completion, an average of 3 months

  4. heart rate

    heart rate

    Time frame: through study completion, an average of 3 months

  5. Hemoglobin concentration

    Hemoglobin concentration assessed by complete blood count

    Time frame: Baseline and every 3 weeks through study completion (up to 3 months)

  6. Left ventricular ejection fraction (LVEF)

    LVEF assessed by echocardiography

    Time frame: Baseline and every 8 weeks through study completion (up to 3 months)

  7. White blood cell count

    White blood cell count assessed by complete blood count

    Time frame: Baseline and every 3 weeks through study completion (up to 3 months)

  8. Platelet count

    Platelet count assessed by complete blood count

    Time frame: Baseline and every 3 weeks through study completion (up to 3 months)

  9. Alanine aminotransferase (ALT) level

    ALT level measured from clinical biochemistry panel

    Time frame: Baseline and every 3 weeks through study completion (up to 3 months)

  10. Aspartate aminotransferase (AST) level

    AST level measured from clinical biochemistry panel

    Time frame: Baseline and every 3 weeks through study completion (up to 3 months)

  11. Creatinine level

    Creatinine level measured from clinical biochemistry panel

    Time frame: Baseline and every 3 weeks through study completion (up to 3 months)

  12. Blood glucose level

    Blood glucose level measured from clinical biochemistry panel (fasting or as specified in protocol)

    Time frame: Baseline and every 3 weeks through study completion (up to 3 months)

  13. Lactate dehydrogenase (LDH) level

    LDH measured from clinical biochemistry panel

    Time frame: Baseline and every 3 weeks through study completion (up to 3 months)

  14. Triiodothyronine (T3) level

    T3 level measured from blood sample.

    Time frame: Baseline and every 3 weeks through study completion (up to 3 months)

  15. Thyroid-stimulating hormone (TSH) level

    TSH levell measured from blood sample.

    Time frame: Baseline and every 3 weeks through study completion (up to 3 months)

  16. Left ventricular end-diastolic diameter (LVEDD)

    LVEDD assessed by echocardiography

    Time frame: Baseline and every 8 weeks through study completion (up to 3 months)

  17. Cardiac output

    Cardiac output estimated by echocardiography

    Time frame: Baseline and every 8 weeks through study completion (up to 3 months)

  18. PR interval

    PR interval assessed by 12-lead electrocardiography

    Time frame: Baseline and every 8 weeks through study completion (up to 3 months)

  19. QRS duration

    QRS duration assessed by 12-lead electrocardiography

    Time frame: Baseline and every 8 weeks through study completion (up to 3 months)

Secondary outcomes

  1. Lymph node target lesion short-axis diameter

    Short axis diameter of target lesions in lymph nodes, assessed by imaging (e. g., utrasonography, CT,or MRI per schedule of assessments

    Time frame: Baseline and every 3 weeks through study completion (up to 3 months)

  2. Percentage of residual viable tumor cells in lymph nodes

    Proportion of viable tumor cells in lymph node tissue assessed by histopathological analysis.

    Time frame: Perioperative (after 3 months of treatment)

07

Study locations

1 of 1 sites recruiting
  • Xijing Hospital, Air Force Medical University Xi'an, Shaanxi, China
    Xi'an, China
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2025 (actual). Primary completion is estimated for Dec 2026, 19 months after the start.

Of 186 non-industry phase 1 interventional studies under Melanoma, half reached primary completion within 52 months of starting (the median), counting those still running; a quarter within 33 and three quarters within 82. This study's planned 19 months is below that.

Counting every sponsor, half of 412 studies reached it within 49 months; a quarter within 31 and three quarters within 76.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 18, 2025
First posted
May 14, 2026
StartActual
May 1, 2025
Primary completionEst.
Dec 2026
CompletionEst.
Jun 2027
Last update
May 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 14, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07586904
Lead sponsor
Xijing Hospital
Responsible party
Sponsor
First posted
May 14, 2026
Start date
May 1, 2025
Primary completion
Dec 2026 (estimated)
Completion
Jun 2027 (estimated)
Last update
May 14, 2026

Study contacts

Weinan Guo
Contact
guown@fmmu.edu.cn
+ 86-29-84775406

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion